An interventional study of regular hemodialysis and hemoperfusion combined with hemodialysis in End Stage Renal Disease, sponsored by Changhai Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.
Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 17th largest by planned enrollment of the 83 interventional ones that give a count, is one of 4 that started in 2023, is one of 40 with no phase, reaches primary completion later than 20 of the 35 other live ones, and was the 73rd registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:
CSL Behring · Sites in China
Ages 18+
Vantive Health LLC · Sites in China
Ages 18–79
Tongji Hospital · Sites in China
Ages 18–65
Yunfeng Xia · Sites in China
Ages 18–75
Longhua Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 9 · Phase 4 18
First in 1996; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 410 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 150 across the 83 interventional studies, 250 across the 31 observational. Of the 55 that completed or were terminated, 7 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 114 have an industry lead sponsor. The 10 most frequent:
Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.
Changhai Hospital has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Failure, Chronic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05639010Changhai HospitalEffects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study | 2026-12-31 |
| NCT07350837Tongji HospitalCAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants | 2026-12-31 |
| NCT07291154Yunfeng XiaImpact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy | 2026-12-31 |
| NCT05315141Xiangya Hospital of Central South UniversityMulticenter Cohort Study of AAV in Hunan of China | 2027-03-16 |
| NCT07303179The First People's Hospital of YunnanExercise Rehabilitation for Functional Impairment in Maintenance Hemodialysis Patients | 2027-06-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 114 studies in Kidney Failure, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-center, open-label, randomized, parallel controlled trial aims to investigate the efficacy of hemoperfusion (HP) in combination with hemodialysis (HD) by assessing blood β2-microglobulin (β2-MG), parathyroid hormone (PTH) and C reactive protein (CRP) clearance in maintenance hemodialysis patients.
In this HD/HP vs HD trial, the investigators plan to enroll 410 maintenance hemodialysis patients. Twelve medical centers in the Shanghai metropolitan area have expressed interest in participating. Participants will be randomized into 2 groups after a 1-month washout period. The control group (205 patients) will be treated with hemodialysis or hemofiltration with a frequency of 3 times/week; the experimental group (205 patients) will be treated with Jafron KHA80 hemoperfusion apparatus in addition to hemodialysis or hemofiltration with a frequency of 1 time/week. Follow-up data before the last dialysis at 4, 12, 24, 36 and 52 weeks of treatment were collected from both groups, including the following: routine physical examination, laboratory tests (blood routine, blood biochemistry, β2-MG, PTH, CRP, liver/kidney function, coagulation system tests, etc.), chest X-ray, electrocardiogram and cardiac ultrasound. Dialysis adequacy as defined by standard Kt/V will be calculated. Comorbidities, combined medications and adverse events will also be captured. The primary outcomes will include change in blood β2-MG, PTH and CRP values. Secondary outcomes will include change values for serum protein-bound toxins (e.g., p-Cresol sulfate, indophenol sulphate), improvement in patient quality of life (Kidney Disease Quality of Life Short Form), sleep disturbance (Pittsburgh Sleep Quality Index) and pruritus (Duo's pruritus score).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
Device: regular hemodialysis
Routine blood purification therapy 3 times a week + Combination of hemodialysis and hemoperfusion treatment once a week
Device: regular hemodialysis · Device: hemoperfusion combined with hemodialysis
Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
Changes in blood β2-microglobulin (β2-MG) values
Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of blood β2-MG in maintenance hemodialysis patients
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Changes in blood Parathyroid Hormone (PTH) values
Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of blood PTH in maintenance hemodialysis patients
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Changes in blood C Reactive Protein (CRP) values
Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of blood CRP in maintenance hemodialysis patients
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Change in serum protein-bound toxin (e.g., p-Cresol sulfate, indophenol sulphate) values
Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of serum protein-bound toxin (e.g., p-Cresol sulfate, indophenol sulphate) in maintenance hemodialysis patients
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Improvement in patients' quality of life
Assessment of quality of life using the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Improvement in patients' sleep disturbance
Assessment of sleep disturbance using the Pittsburgh Sleep Quality Index (PSQI)
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Improvement in patients' pruritus
Assessment of pruritus using the Duo's pruritus score
Time frame: From date of enrollment until the end of study, assessed up to 52 weeks
Plan to share: Yes — Individual participant data that underlie the results reported in the publication article, after deidentification (text, tables, figures, and appendices), will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The available data period begins 3 months and ends 5 years following the article's publication.
Access criteria: Investigators who provide a methodologically sound proposal for scientific research with non-commercial purposes will be able to access the IPD and supporting information. Deidentified participant data that underlie the results reported in the publication article will be shared, which can be available from Professor Zhiyong Guo (contacting email: drguozhiyong@163.com, ORCID: Shenneike66). Proposals should be directed to drguozhiyong@163.com. To gain access, data requestors will need to sign a data access agreement.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 47 months is above that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.